Terms: = Lung cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Treatment
30385 results:
1. Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Wang H; Hu Q; Chen Y; Huang X; Feng Y; Shi Y; Li R; Yin X; Song X; Liang Y; Zhang T; Xu L; Dong G; Jiang F
Nat Commun; 2024 May; 15(1):4195. PubMed ID: 38760351
[TBL] [Abstract] [Full Text] [Related]
2. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract] [Full Text] [Related]
3. Strategies to address recruitment to a randomised trial of surgical and non-surgical treatment for cancer: results from a complex recruitment intervention within the Mesothelioma and Radical Surgery 2 (MARS 2) study.
Mills N; Farrar N; Warnes B; Ashton KE; Harris R; Rogers CA; Lim E; Elliott D
BMJ Open; 2024 May; 14(5):e079108. PubMed ID: 38760029
[TBL] [Abstract] [Full Text] [Related]
4. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
5. Clinic information, pathological, and imaging characteristics in 2 058 surgical patients with lung cancer from a single center.
Long B; Xiong Z; Liu S; Cheng Y; Li M; Liao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):247-255. PubMed ID: 38755720
[TBL] [Abstract] [Full Text] [Related]
6. Non-Small Cell lung cancer, Version 4.2024.
Riely GJ; Wood DE; Ettinger DS; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Desai AP; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Juloori A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Mullikin TC; Ng T; Owen D; Owen DH; Patel SP; Patil T; Polanco PM; Riess J; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hang L
J Natl Compr Canc Netw; 2024 May; 22(4):249-274. PubMed ID: 38754467
[TBL] [Abstract] [Full Text] [Related]
7. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
8. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of sex inequity in lung-cancer-specific survival.
Lærum D; Strand TE; Brustugun OT; Gallefoss F; Falk R; Durheim MT; Fjellbirkeland L
Acta Oncol; 2024 May; 63():343-350. PubMed ID: 38751329
[TBL] [Abstract] [Full Text] [Related]
10. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract] [Full Text] [Related]
11. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
12. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
13. Perioperative Nivolumab in Resectable lung cancer.
Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
[TBL] [Abstract] [Full Text] [Related]
14. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
15. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
Suzuki S
Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
[TBL] [Abstract] [Full Text] [Related]
16. Prediction of Prognostic Features Based on Neutrophil-Related Genes for lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates.
Sili D; Nan Z
Rev Invest Clin; 2024; 76(2):116-131. PubMed ID: 38740381
[TBL] [Abstract] [Full Text] [Related]
17. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
18. High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.
Tajiri A; Tsujii Y; Nishida T; Inoue T; Maekawa A; Kitamura S; Yamaguchi S; Nishihara A; Yamada T; Ogiyama H; Murayama Y; Yamamoto S; Egawa S; Uema R; Yoshihara T; Hayashi Y; Takehara T
Cancer Med; 2024 May; 13(9):e7242. PubMed ID: 38733176
[TBL] [Abstract] [Full Text] [Related]
19. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract] [Full Text] [Related]
20. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.
Xiao B; Li G; Gulizeba H; Liu H; Sima X; Zhou T; Huang Y
J Transl Med; 2024 May; 22(1):442. PubMed ID: 38730286
[TBL] [Abstract] [Full Text] [Related]
[Next]
